CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry

Part of paid clinical trials in Waltham, Massachusetts.

Sponsor
CorEvitas
Study ID
NCT01402661
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for RA in a cohort of patients cared for by rheumatologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.

Key Dates

Start date
Feb 28, 2002
Status verified
Sep 2025
Primary completion
Dec 31, 2100
Completion
Dec 31, 2100

Study Design

Enrollment
91,758 participants (estimated)

Arms

  • Arm: Rheumatoid Arthritis
    Pts presenting to enrolling sites across the US are invited to enroll if eligible.

Primary Outcome Measure

Patterns, effectiveness, and safety of DMARDs, biologic agents and any other treatments currently used in the management of RA [ Time Frame: Data are collected on subjects for as long as they consent to remain in the study ]

Locations (1)

FacilityCityStateZIPSite coordinators
CorEvitas, LLCWalthamMassachusetts02451-

Find similar trials in Waltham, MA

By condition
Rheumatoid arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
CorEvitas, LLC· Waltham, MA

Related Studies